[go: up one dir, main page]

WO2006071897A3 - Treatment of macular degeneration with lonidamine - Google Patents

Treatment of macular degeneration with lonidamine Download PDF

Info

Publication number
WO2006071897A3
WO2006071897A3 PCT/US2005/047145 US2005047145W WO2006071897A3 WO 2006071897 A3 WO2006071897 A3 WO 2006071897A3 US 2005047145 W US2005047145 W US 2005047145W WO 2006071897 A3 WO2006071897 A3 WO 2006071897A3
Authority
WO
WIPO (PCT)
Prior art keywords
lonidamine
macular degeneration
treatment
administering
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/047145
Other languages
French (fr)
Other versions
WO2006071897A2 (en
Inventor
George Tidmarsh
Steve Ammons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Templates Inc
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of WO2006071897A2 publication Critical patent/WO2006071897A2/en
Publication of WO2006071897A3 publication Critical patent/WO2006071897A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Macular degeneration is treated by administering a therapeutically effective amount of lonidamine or a lonidamine analog.
PCT/US2005/047145 2004-12-23 2005-12-22 Treatment of macular degeneration with lonidamine Ceased WO2006071897A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63905504P 2004-12-23 2004-12-23
US60/639,055 2004-12-23

Publications (2)

Publication Number Publication Date
WO2006071897A2 WO2006071897A2 (en) 2006-07-06
WO2006071897A3 true WO2006071897A3 (en) 2006-10-19

Family

ID=36615495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/047145 Ceased WO2006071897A2 (en) 2004-12-23 2005-12-22 Treatment of macular degeneration with lonidamine

Country Status (2)

Country Link
TW (1) TW200633705A (en)
WO (1) WO2006071897A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008001811A1 (en) * 2008-05-15 2009-11-19 Beiersdorf Ag Cosmetic preparations for reducing sweat odor with ABCC modulators
KR102377008B1 (en) * 2019-07-01 2022-03-21 서울대학교산학협력단 Pharmaceutical composition for preventing or treating angiogenesis relating ocular diseases comprising inhibitors of MCT expression or activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482802B1 (en) * 1998-05-11 2002-11-19 Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482802B1 (en) * 1998-05-11 2002-11-19 Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases

Also Published As

Publication number Publication date
WO2006071897A2 (en) 2006-07-06
TW200633705A (en) 2006-10-01

Similar Documents

Publication Publication Date Title
WO2005102335A3 (en) Methods of treating sleep disorders
WO2007087468A3 (en) Adiponectin for treatment of various disorders
WO2006102374A3 (en) Bioactive wide-weave mesh
WO2007098089A3 (en) Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs
WO2005096990A3 (en) Novel modification of medical prostheses
WO2008000513A3 (en) Peptide compounds for the treatment of hyperexcitability disorders and diseases associated with ion channel dysfunction
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2007098091A3 (en) Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2007095389A3 (en) Treatment of hyperproliferative diseases with camptothecine n-oxide and analogs
WO2008090287A3 (en) Use of at least one botulism neurotoxin for treating the pain induced by therapeutic treatments for the aids virus
WO2005107872A3 (en) Treating respiratory diseases with gycopyrrolate and analogues
WO2005118609A3 (en) Small molecule stimulators of neuronal growth
WO2006113978A3 (en) Insulins combinations
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
GB0521716D0 (en) Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
WO2006071897A3 (en) Treatment of macular degeneration with lonidamine
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
AU2003240545A1 (en) Use of ramoplanin to treat diseases associated with the use of antibiotics
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05855663

Country of ref document: EP

Kind code of ref document: A2